ArticleNeurology2017
Cortical superficial siderosis multifocality in cerebral amyloid angiopathy: A prospective study.
Abstract read
In one paragraph
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 3 pooled it
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Risk factors for recurrent cerebral amyloid angiopathy-related intracerebral hemorrhage.Frontiers in neurology · 2023Pooled it
- Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis.Neurology · 2019Pooled it
- Pooled it
- Primary acute convexity subarachnoid hemorrhage in older patients: analysis of baseline, clinical and MRI characteristics including quantitative surface study and topographical probabilistic mapping of convexity subarachnoid hemorrhage.Acta neurologica Belgica · 2023Trial
- Trial
- Early vs Delayed Steroid Treatment in Cerebral Amyloid Angiopathy-Related Inflammation: A Retrospective Cohort Study.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Plasma Amyloid Beta and Tau Associations with Cerebral Amyloid Angiopathy Presence and Severity.Annals of neurology · 2026Article
- Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.Neurology · 2026Article
- Hemorrhage Pattern and Amyloid Burden in Cerebral Amyloid Angiopathy.Journal of the American Heart Association · 2026Article
- Associations of Neutrophil-to-Lymphocyte Ratio with Cerebral Small Vessel Disease and Functional Outcome in Acute Ischaemic Stroke Patients.Life (Basel, Switzerland) · 2026Article
- Effects of Heavy Alcohol Use on Acute Intracerebral Hemorrhage and Cerebral Small Vessel Disease.Neurology · 2025Article
- Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes.Journal of the American Heart Association · 2025Article
- One-Year Radiologic Progression in Sporadic and Hereditary Cerebral Amyloid Angiopathy.Neurology · 2025Article
- Cerebrospinal Fluid Beta-Amyloid Concentration and Clinical and Radiographic Manifestations of Cerebral Amyloid Angiopathy.Journal of the American Heart Association · 2025Article
- Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage.JAMA neurology · 2025Article
- Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease.Journal of clinical medicine · 2025Review
- Left atrial appendage closure for patients with atrial fibrillation at high intracranial haemorrhagic risk.Stroke and vascular neurology · 2025Article
- Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy.European journal of neurology · 2025Article
- Characterizing the underlying microangiopathy of deep cerebellar intracerebral hemorrhage.Journal of neurology · 2025Article
- Associations of inferior frontal sulcal hyperintensities on brain MRI with cerebral small vessel disease, cognitive function, and depression symptoms.Scientific reports · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 2 countries.
Andreas CharidimouFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Gregoire BoulouisFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Duangnapa RoongpiboonsopitFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Eitan AurielFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Marco PasiFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Kellen HaleyFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Ellis S van EttenFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Sergi Martinez-RamirezFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Alison AyresFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Anastasia VashkevichFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Kristin M SchwabFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Joshua N GoldsteinFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Jonathan RosandFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Anand ViswanathanFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
Steven M GreenbergFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel.
M Edip GurolFrom the Hemorrhagic Stroke Research Program, Department of Neurology, Stroke Research Center (A.C., G.B., D.R., E.A., M.P., K.H., E.S.v.E., S.M.-R., A.A., A. Vashkevich, K.M.S., J.N.G., J.R., A. Viswanathan, S.M.G., M.E.G.), and Division of Neurocritical Care and Emergency Neurology (J.N.G., J.R.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurology (E.A.), Carmel Medical Center, Haifa, Israel. edip@mail.harvard.edu.
Carmel Medical Center · IL
Funding
Vascular Dysfunction in Cerebral Amyloid AngiopathyR01AG026484 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBERG, STEVEN M · 2005 to 2019
$7.5MVascular Pathology in Early and Asymptomatic Cerebral Amyloid AngiopathyR01AG047975 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VISWANATHAN, ANAND · 2014 to 2025
$7.5MEarly Detection of Cerebral Amyloid AngiopathyR01NS070834 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBERG, STEVEN M · 2010 to 2014
$2.3MMolecular Neuroimaging of Disease Mechanisms in Cerebral Amyloid AngiopathyK23NS083711 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GUROL, MAHMUT EDIP · 2014 to 2018
$988kNIA NIH HHS R01 AG026484NIA NIH HHS R01 AG047975NINDS NIH HHS K23 NS083711NINDS NIH HHS R01 NS070834
Abstract
objectiveIn order to explore the mechanisms of cortical superficial siderosis (cSS) multifocality and its clinical implications for recurrent intracerebral hemorrhage (ICH) risk in patients with cerebral amyloid angiopathy (CAA), we used a new rating method that we developed specifically to evaluate cSS extent at spatially separated foci.
methodsConsecutive patients with CAA-related ICH according to Boston criteria from a single-center prospective cohort were analyzed. The new score that assesses cSS multifocality (total range 0-4) showed excellent interrater reliability (k = 0.87). The association of cSS with markers of CAA and acute ICH was investigated. Patients were followed prospectively for recurrent symptomatic ICH.
resultsThe cohort included 313 patients with CAA. Multifocal cSS prevalence was 21.1%.
conclusionsThe multifocality of cSS correlates with disease severity in probable CAA; therefore cSS is likely to be caused by discrete hemorrhagic foci. The new cSS scoring system might be valuable for clinicians in determining annual risk of ICH recurrence.
Indexed as
AgedAged, 80 and overApolipoproteins ECerebral Amyloid AngiopathyCerebral CortexCerebral HemorrhageCohort StudiesFemaleHumansKaplan-Meier EstimateMagnetic Resonance ImagingMaleProportional Hazards ModelsSeverity of Illness IndexSiderosisApolipoproteins E
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.